



**REVIEW ARTICLE**

**METASTATIC CANCERS TO THE ORAL CAVITY: AN OVERVIEW**

Georges Aoun<sup>1\*</sup>, Wissam Sharrouf<sup>2</sup>, Samia El Azab<sup>3</sup>

<sup>1</sup>Professor and Former Dean, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon

<sup>2</sup>Professor, Research and Maxillofacial Surgery Departments, Faculty of Dentistry, Aqaba Medical Sciences University, Aqaba, Jordan

<sup>3</sup>Professor and Dean, Faculty of Dentistry, Aqaba Medical Sciences University, Aqaba, Jordan

\*Correspondence: Georges Aoun; Professor and Former Dean, Faculty of Dental Medicine, Lebanese University, Beirut, Lebanon e-mail: dr.georgesoun@gmail.com

Received: Mar 15. 2026; Accepted: Apr 21. 2026; Published: Apr 27. 2026

**Abstract**

Metastasis is a complex biological process that begins when cancer cells separate from the original tumor and spread to other tissues and organs, causing morbidity and death. Metastatic cancers to the oral cavity are rare and frequently associated with widespread disease. The diagnosis of these tumors is challenging, and their prognosis is poor. The purpose of this paper is to review the pathogenesis, clinical and histological features, treatment options, and prognosis of metastatic cancers that affect the oral cavity.

**Keywords:** Cancer, metastasis, oral cavity.

**INTRODUCTION**

According to the National Cancer Institute, cancer is a disease in which some of the body's cells grow uncontrollably and may spread to other parts of the body.<sup>1</sup> It is characterized by complex, sequential, and irreversible dysregulated processes. Metastasis is a complex biological process that initiates with the detachment of cancer cells from the primary tumor, followed by dissemination into distant tissues and organs, resulting in morbidity and mortality.<sup>2</sup>

Metastatic cancers to the oral cavity are rare (1% to 3% of all malignant oral neoplasms) and frequently

associated with widespread disease and poor prognosis. They can affect the soft tissues of the mouth, the jawbones, or both of them.<sup>2,3</sup> The kidney, the lung, the breast, the prostate, the bone, the colon, and the adrenal gland are among the initial sites of malignancies that spread to the oral region, and the mandible, especially the molar region, is the most frequently involved site.<sup>4,5</sup>

The distribution of primary tumors and their typical oral metastatic patterns is summarized in Table 1.

**Table 1. Primary Tumor Sites and Frequency of Oral Metastasis**

| Primary tumor site | Relative frequency | Common oral location  | Typical pattern                    |
|--------------------|--------------------|-----------------------|------------------------------------|
| Lung               | High               | Gingiva, jawbones     | Osteolytic, fast-growing           |
| Breast             | High               | Mandible, soft tissue | Mixed lytic/blastic                |
| Kidney             | Moderate–High      | Gingiva, tongue       | Highly vascular soft tissue mass   |
| Prostate           | Moderate           | Mandible              | Osteoblastic lesions               |
| Colon/Rectum       | Low–Moderate       | Jawbones              | Osteolytic lesions                 |
| Thyroid            | Low                | Jawbones/soft tissue  | Vascular lesion, bleeding tendency |
| Adrenal gland      | Rare               | Mandible              | Osteolytic destructive lesion      |

Clinically, metastatic cancers to the oral cavity often show non-aggressive signs that look like harmless or reactive lesions or even simple odontogenic infections; consequently, it may be difficult for both the pathologist and the dentist to diagnose them.<sup>2</sup> Actually, the pathologist must identify the location of the tumor's origin, and the clinician must recognize the possibility that a lesion could be a metastasis. These tumors are very important from a clinical perspective because they could represent the first symptom of an undetected cancer at a distant primary site or the first sign of a known tumor spreading from its originating site.<sup>2,5,6</sup> The aim of this paper was to review the pathogenesis and clinical and histological features, as well as the treatment and prognosis of metastatic cancers to the oral cavity.

**Epidemiology**

Metastatic cancers to the oral cavity are rare, occurring in about 1% to 3% of cases.<sup>7-9</sup> They are mostly patients aged between 40 and 70 years. Generally, in young patients, metastases are in jaw bones more than in soft tissues. The male-to-female ratio of metastases in oral soft tissues was 2:1, while the distribution in the jawbone was nearly equal by gender.<sup>2</sup> A systematic review conducted by Macedo et al. and published in 2023 found that male patients represented the majority (1.7:1), and most of them were in their sixth decade of life. In 51% of cases, the oral metastatic lesion was the initial indication of malignancy. Furthermore, 60% of them developed metastases to other locations by the time of clinical evaluation.<sup>10</sup> Soft tissues, especially the gingiva, account for 58% of oral cavity metastases; the jaws account for 42%, with the mandible having the highest prevalence (89%). The lungs were the most frequently reported primary site of metastatic lesions in the jaws and oral soft tissues.<sup>7,10</sup>

**Pathogenesis**

Metastasis refers to the process by which a primary tumor invades surrounding tissues and disseminates cancer cells through lymphatic or blood vessels. As these circulating cancer cells travel throughout the body, they can survive and eventually settle in the microvasculature of target organs, where they extravasate through the walls of blood vessels.

These cancer cells enter and progress toward visible metastases. The tumor microenvironment and/or the functions of the cancer cells themselves support these phases.<sup>2,11</sup> Cancer cells must have specific characteristics that enable them to survive in new environments. In fact, the establishment of a successful metastatic area depends on these cells' ability to maintain distinct microenvironments throughout the metastatic process. Furthermore, angiogenesis and revascularization, which involve creating new blood vessels, are essential for tumor growth.<sup>2,11-13</sup> The formation of the tumor vasculature depends on numerous proangiogenic and antiangiogenic, inflammatory, and coagulation factors.<sup>2,14,15</sup> Additionally, hypoxia within the tumor mass stimulates angiogenesis during the early stages of tumor growth by promoting the up-regulation of specific transcription factors that regulate proangiogenic signals, primarily the vascular endothelial growth factors (VEGFs).<sup>14-17</sup> Considerable evidence suggests that the spread of various types of cancer to distant organs is a controlled, site-specific process rather than an accidental occurrence.<sup>2,12</sup> Several studies show that many molecular pathways are involved in the lymphatic and hematogenous dissemination of various malignancies.

The oral region is not a favored site for the initial spread of a cancer from its original site but is usually the result of secondary spread from other metastatic lesions. In fact, it is unclear what causes the metastatic cancers in the jawbones. Bone, especially the one with red marrow, is often regarded as a preferred site for the metastatic process by many primary malignancies, particularly those originating in the lungs, breast, prostate, and kidneys.<sup>2,18</sup> Although jawbones typically contain minimal active marrow, particularly in older adults, remnants of hematopoietic active marrow can still be found in the posterior regions of the mandible. These areas are known to attract metastatic tumor cells.<sup>2</sup> As for the oral soft tissues having a rich complex of capillaries, they can easily capture malignant cells. Additionally, chronic inflammation is associated with various stages of tumorigenesis, such as cellular transformation, promotion, survival, proliferation, invasion, angiogenesis, and metastasis.<sup>4,19</sup>

**Clinical features**

The clinical features of metastatic cancers to the oral cavity are variable. A comparative overview of the main differences between soft tissue and jawbone metastases is presented in Table 2.

**Table 2. Clinical Features: Oral Soft Tissue vs Jawbone Metastases**

| <b>Feature</b>   | <b>Soft tissue metastasis</b> | <b>Jawbone metastasis</b>          |
|------------------|-------------------------------|------------------------------------|
| Most common site | Gingiva, tongue               | Posterior mandible                 |
| Growth rate      | Rapid                         | Moderate-rapid                     |
| Pain             | Variable                      | Common                             |
| Swelling         | Exophytic mass                | Intraosseous expansion             |
| Ulceration       | Frequent                      | Less frequent                      |
| Bleeding         | Very common                   | Occasional                         |
| Paresthesia      | Rare                          | Common (“numb chin syndrome”)      |
| Misdiagnosis     | Pyogenic lesion, hyperplasia  | Osteomyelitis, cyst, periodontitis |

Metastatic cancers to the oral cavity can grow fast, causing pain, dysphagia, disfigurement, and intermittent bleeding.

The majority of them presented as tumors, masses, and swelling, mostly larger than 10 mm in diameter. In the soft tissues, the most commonly involved site is the attached gingiva, preceded by the tongue. The lesions are typically firm and irregular, with or without an ulcerated surface, and they are more often associated with bleeding compared to those in the jaws, which were frequently linked to pain, paresthesia, and sometimes pathological fractures.<sup>8,10</sup> In some cases, metastases are discovered after a recent dental extraction; a painful soft mass extruding from the extraction site is the main symptom.<sup>2</sup>

This schematic illustrates the distribution and key clinical characteristics of oral metastatic lesions, divided into two main categories: soft tissue and jawbone involvement. Soft tissue metastases account for approximately 58% of cases and most commonly affect the gingiva, followed by the tongue and palate. These lesions typically present as rapidly growing exophytic masses with frequent ulceration and bleeding. Jawbone metastases represent approximately 42% of cases, with the posterior mandible being the most commonly involved site, while the maxilla is less frequently affected. Clinically, jawbone lesions are associated with pain, paresthesia (including “numb chin syndrome”), pathological fractures, and radiographic “moth-eaten” radiolucency. This comparison highlights the distinct clinical behavior and diagnostic features of soft tissue versus osseous metastatic involvement in the oral cavity (figure1).




Figure 1. Oral Metastasis Clinical Pattern Map

According to many studies, tooth extraction can serve as a promoting factor in the metastatic process.<sup>8,9,10</sup> Furthermore, the oral metastatic lesion may be the first sign of an undiscovered malignancy at a distant site.<sup>20,21</sup>

**Radiological features**

Traditional oncology imaging techniques, such as echography, X-ray, CT, and MRI, have been utilized for radiological assessments of cancers, but diagnostic decisions were often limited by low precision. Subsequently, significant advancements in oncologic imaging have revolutionized cancer diagnosis, treatment planning, and monitoring, offering the clinicians valuable insights into tumor characteristics and their responses to therapies. For instance, dual-modality imaging like PET/CT and SPECT/CT combines anatomical, metabolic, and functional information for more accurate disease assessment.<sup>22</sup>

As for the radiographic appearance, metastatic cancers to the oral cavity do not possess a specific one. They can be anything from an osteolytic or opaque lesion with unclear borders to the absence of any signs.<sup>2</sup> The balance between osteoblastic and osteoclastic activity generally determines the characteristics of metastatic bone lesions.<sup>23</sup> Metastases originating from prostate cancer almost always result in the formation of osteoblastic lesions within the bone. In contrast, bone metastases from kidney, lung, or breast cancers tend to be more osteolytic. Furthermore, these lesions may occasionally show up as a single radiolucency of the jawbone that mimics osteomyelitis or an infected cyst. A summary of radiographic characteristics according to primary tumor type is provided in Table 3.

Table 3. Radiographic Characteristics by Primary Tumor Type

| Primary tumor | Radiographic pattern      | Key diagnostic clue              |
|---------------|---------------------------|----------------------------------|
| Prostate      | Osteoblastic (radiopaque) | Dense sclerotic bone             |
| Kidney        | Osteolytic                | “Moth-eaten” destruction         |
| Lung          | Osteolytic / mixed        | Poorly defined radiolucency      |
| Breast        | Mixed pattern             | Cortical destruction + expansion |
| Thyroid       | Radiolucent, vascular     | Bleeding tendency                |
| Colon         | Osteolytic                | Aggressive bone loss             |

The bone may have a moth-eaten look, which is characterized by numerous tiny, ill-defined holes. The cortical bone of adjacent structures, including the nasal floor, maxillary sinus, and mandibular canal, could be resorbed.<sup>2</sup>

**Histological features**

The diagnosis of metastatic cancers to the oral cavity is challenging. An incisional biopsy and histopathologic examination are essential to confirm the malignancy of the lesion and potentially its metastatic origin. Furthermore, these lesions present variable histological appearances. In case of a previous tumor history, the microscopic findings of the oral lesion should be compared with those of the primary tumor. However, due to the heterogeneity and sometimes nonspecific features of these lesions, adjunctive techniques are frequently necessary. Special staining aids in identifying specific cellular components, while immunohistochemistry plays a central role in detecting tumor-specific markers and narrowing the primary site. In diagnostically challenging cases, electron microscopy may provide additional ultrastructural detail.<sup>2,24,25</sup>

Table 4 summarizes the integrative approach to histological diagnosis of oral metastatic lesions.

**Table 4. Histological Diagnostic Approach for Oral Metastatic Lesions**

| <b>Diagnostic Method</b>      | <b>Purpose</b>             | <b>Key Findings / Role</b>                     | <b>Clinical Relevance</b>                      |
|-------------------------------|----------------------------|--|--|
| Incisional Biopsy             | Initial tissue sampling    | Confirms presence of malignant cells           | Essential first step in diagnosis              |
| Histopathologic Examination   | Microscopic evaluation     | Identifies tumor type, differentiation pattern | Helps distinguish primary vs metastatic lesion |
| Comparison with Primary Tumor | Correlation analysis       | Similar morphology with known primary cancer   | Strong evidence of metastatic origin           |
| Special Staining              | Cellular characterization  | Highlights mucin, keratin, or other components | Supports tumor subtype identification          |
| Immunohistochemistry (IHC)    | Detection of tumor markers | Expression of CK7, CK20, TTF-1, PSA, etc.      | Critical for identifying primary site          |
| Electron Microscopy           | Ultrastructural analysis   | Detailed cellular architecture                 | Used in difficult or ambiguous cases           |

Overall, accurate diagnosis of oral metastatic disease requires a multidisciplinary and multimodal approach, integrating conventional histopathology with advanced diagnostic techniques to ensure precise tumor identification and appropriate clinical management.

**Prognosis and management**

Metastatic cancers to the oral cavity are usually evidence of a widespread disease and represent a poor prognosis.<sup>26,27</sup> As for the treatment, if the primary tumor has been successfully treated and the patient's medical condition allows, the metastatic lesion should be treated aggressively. Treatment options may include surgical resection, radiation, chemotherapy, or a combination of these methods. However, if the primary tumor has recurred or if there are widespread metastases, the approach to managing the jaw lesion should be more conservative, aiming to relieve the patient's pain while preserving oral function. This approach may include methods such as radiotherapy, chemotherapy, or local surgical excision to reduce the size of the tumor.<sup>2,28</sup>

**Stepwise Diagnostic Approach for the Evaluation of Oral Metastatic Lesions**

The diagnostic workup of oral metastatic lesions follows a structured, stepwise approach that integrates clinical evaluation, imaging modalities, and histopathological confirmation. Initially, a thorough clinical examination is essential to identify suspicious lesions and assess their morphology, location, and associated symptoms. Radiographic evaluation, including orthopantomogram (OPG) and computed tomography (CT), is then used to detect bone destruction and evaluate the extent of osseous involvement. Magnetic resonance imaging (MRI) provides superior soft tissue contrast and is particularly useful for assessing tumor extension into adjacent anatomical structures.<sup>29,30</sup> Positron emission tomography/computed tomography (PET/CT) plays a critical role in whole-body staging by identifying both the primary tumor and additional metastatic sites. Definitive diagnosis relies on biopsy and

histopathological examination of the lesion. Subsequently, immunohistochemical analysis is employed to determine the tumor's tissue of origin. In selected cases, molecular markers such as cytokeratin profiles (CK7, CK20), prostate-specific antigen (PSA), and other tumor-specific markers are used to further confirm the primary source of the metastasis.<sup>22, 3</sup> The complete diagnostic pathway is summarized in Table 5.

**Table 5. Diagnostic Approach to Oral Metastatic Lesions**

| Step | Diagnostic tool       | Purpose                                     |
|------|-----------------------|---|
| 1    | Clinical examination  | Identify suspicious lesion                  |
| 2    | Radiography (OPG, CT) | Detect bone destruction                     |
| 3    | MRI                   | Soft tissue extension                       |
| 4    | PET/CT                | Identify primary tumor + metastases         |
| 5    | Biopsy                | Histopathological confirmation              |
| 6    | Immunohistochemistry  | Tumor origin identification                 |
| 7    | Molecular markers     | Confirm primary site (CK7, CK20, PSA, etc.) |

## CONCLUSION

Diagnosing a metastatic lesion in the oral region is challenging, and the prognosis for these lesions is poor; alleviating symptoms is the aim of the therapeutic modality needed. Adequate clinical and histopathological assessments are required for a definitive diagnosis of the lesion and its origin.

## Limitations

## DECLARATIONS

### Ethical Approval

Not applicable.

### Consent to Participate

Not applicable.

### Competing Interests

The authors declare no conflict of interest.

### Funding

None.

### Acknowledgments

None.

## REFERENCES

- National Cancer Institute. What is cancer? Available from: <https://www.cancer.gov/about-cancer/understanding/what-is-cancer>.
- Kumar G, Manjunatha B. Metastatic tumors to the jaws and oral cavity. *J Oral Maxillofac Pathol*. 2013; 17(1): 71-75. doi: 10.4103/0973-029X.110737.
- Ho DP, Wilkinson PE, Vogel RI, Gopalakrishnan R, Argyris PP. Metastatic tumors to the oral soft tissues and jawbones: a retrospective analysis of 40 cases and review of the literature. *Head Neck Pathol*. 2022; 16(3): 802-813. doi: 10.1007/s12105-022-01451-8.
- Hirshberg A, Leibovich P, Buchner A. Metastases to the oral mucosa: analysis of 157 cases. *J Oral Pathol Med*. 1993; 22(9): 385-390. doi: 10.1111/j.1600-0714.1993.tb00128.x.
- Aoun G, Hayek E, Nasseh I. Mandibular metastasis of a recurrent poorly differentiated urothelial bladder carcinoma. *J Clin Imaging Sci*. 2020; 10: 27. doi: 10.25259/JCIS\_46\_2020.
- Bodner L, Sion-Vardy N, Geffen DB, Nash M. Metastatic tumors to the jaws: a report of eight new cases. *Med Oral Patol Oral Cir Bucal*. 2006; 11(2): E132-E135.
- Irani S. Metastasis to the oral soft tissues: A review of 412 cases. *J Int Soc Prev Community Dent*. 2016; 6(5): 393-401. doi:10.4103/2231-0762.192935.
- Hirshberg A, Shnaiderman-Shapiro A, Kaplan I, Berger R. Metastatic tumours to the oral cavity - pathogenesis and analysis of 673 cases. *Oral Oncol*. 2008;44(8):743-752. doi:10.1016/j.oraloncology.2007.09.012.
- van der Waal RI, Buter J, van der Waal I. Oral metastases: report of 24 cases. *Br J Oral Maxillofac Surg*. 2003; 41(1): 3-6. doi:10.1016/s0266-4356(02)00301-7.
- Macedo LF, Falcão AP, de Campos WG, Lemos Júnior CA, Miguita L, Domaneschi C. Metastasis to the oral cavity: a systematic review. *Res Soc Dev*. 2023; 12(2): e3512237418. doi:10.33448/rsd-v12i2.37418.
- Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. *Nat Rev Cancer*. 2009; 9(4): 239-252. doi:10.1038/nrc2618.
- Nguyen DX, Bos PD, Massagué J. Metastasis: from dissemination to organ-specific colonization. *Nat Rev Cancer*. 2009; 9(4): 274-284. doi:10.1038/nrc2622.
- Folkman J. Role of angiogenesis in tumor growth and metastasis. *Semin Oncol*. 2002; 29(6 Suppl 16): 15-18. doi: 10.1053/sonc.2002.37263.
- Bishop-Bailey D. Tumour vascularisation: a druggable target. *Curr Opin Pharmacol*. 2009; 9(2): 96-101. doi: 10.1016/j.coph.2008.10.004.
- Naumov GN, Bender E, Zurakowski D, Kang SY, Sampson D, Flynn E, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. *J Natl Cancer Inst*. 2006; 98(5): 316-325. doi: 10.1093/jnci/djj068.

16. Christofori G. New signals from the invasive front. *Nature*. 2006; 441(7092): 444-450. doi: 10.1038/nature04872.
17. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. *Nat Med*. 2003; 9(6): 677-684. doi: 10.1038/nm0603-677.
18. Sowder ME, Johnson RW. Bone as a preferential site for metastasis. *JBMR Plus*. 2019; 3(3): e10126. doi: 10.1002/jbm4.10126.
19. Hirshberg A, Leibovich P, Buchner A. Metastatic tumors to the jawbones: analysis of 390 cases. *J Oral Pathol Med*. 1994; 23(8): 337-341. doi: 10.1111/j.1600-0714.1994.tb00072.x.
20. Hirshberg A, Buchner A. Metastatic tumours to the oral region. An overview. *Eur J Cancer B Oral Oncol*. 1995;31B(6):355-360. doi: 10.1016/0964-1955(95)00031-3.
21. Clausen F, Poulsen H. Metastatic carcinoma of the jaws. *Acta Pathol Microbiol Scand*. 1963;57:361-374. doi: 10.1111/j.1699-0463.1963.tb05105.x.
22. Wang T, Ni Y, Liu L. Innovative imaging techniques for advancing cancer diagnosis and treatment. *Cancers (Basel)*. 2024;16(14):2607. doi: 10.3390/cancers16142607.
23. Lin SC, Yu-Lee LY, Lin SH. Osteoblastic factors in prostate cancer bone metastasis. *Curr Osteoporos Rep*. 2018;16(6):642-647. doi: 10.1007/s11914-018-0480-6.
24. Kabir IM, Idris AT, Abubakar SD, Isah MM, Usman A, Yusuf L, et al. Immunohistochemistry as an indispensable tool in oncology. *Indian J Gynecol Oncolog*. 2024;22:106. doi:10.1007/s40944-024-00875-0.
25. Ordóñez NG, Mackay B. Electron microscopy in tumor diagnosis: indications for its use in the immunohistochemical era. *Hum Pathol*. 1998;29(12):1403-1411. doi: 10.1016/s0046-8177(98)90008-9.
26. Asoda S, Yasui T, Tanaka K, Onizawa K, Kawana H, Nakagawa T. A systematic review of metastatic lesions to the oral and maxillofacial regions among Japanese people. *Jpn Dent Sci Rev*. 2025;61:155-166. doi: 10.1016/j.jdsr.2025.06.001.
27. Atarbashi-Moghadam S, Atarbashi-Moghadam F, Niazmand M, Shahrabi-Farahani S. Metastatic sarcomas of the oral cavity: A systematic review. *J.Stomatol Oral Maxillofac Surg*. 2024;125(2):101656. doi: 10.1016/j.jormas.2023.101656.
28. Wood NK, Goaz PW. Differential diagnosis of oral and maxillofacial lesions. 5th edition. St Louis: Mosby; 1997. pp. 346-347.
29. Kirschnick LB, Schuch LF, Gondak R, Rivero ERC, Gomes APN, Etges A, et al. Clinicopathological features of metastasis to the oral and maxillofacial region-multicenter study. *Head Neck Pathol*. 2023;17(4):910-920. doi: 10.1007/s12105-023-01588-0.
30. Hirshberg A, Berger R, Allon I, Kaplan I. Metastatic tumors to the jaws and mouth: analysis and current concepts. *Head Neck Pathol*. 2021;15(2):463-474. doi: 10.1007/s12105-020-01252-3.
31. Bishop JA, Westra WH. Cytokeratin immunoprofiles and their diagnostic utility in metastatic carcinomas. *Arch Pathol Lab Med*. 2022;146(1):48-57. doi: 10.5858/arpa.2020-0789-RA.



Copyright © 2026 by author(s) and "ASTRA SCIENCE" L L C This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

<https://creativecommons.org/licenses/by-nc/4.0/>